- Investing Ideas
- /
- German Undervalued Stocks Based On Cash Flows
German Undervalued Stocks Based On Cash Flows
Results
28
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
28 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
CY1K | €2.94 | -5.2% | -58.0% | €28.7m | €7.00 | PB0.9x | E102.7% | n/a | Capital Goods | ||
PSAN | €22.50 | 0% | -29.5% | €348.5m | €30.18 | PS1.3x | E59.8% | 1.8% | Software | ||
CHG | €24.60 | 3.4% | 73.2% | €446.5m | €27.00 | PS6.3x | E73.4% | n/a | Healthcare | ||
SBS | €44.50 | -2.0% | -26.7% | €540.9m | €42.33 | PE44.5x | E21.9% | 1.2% | Healthcare | ||
R1B | €5.90 | 0% | -4.8% | €21.2m | €12.00 | PS25.6x | E77.5% | n/a | Software | ||
STM | €44.85 | -2.1% | -13.2% | €1.1b | €63.44 | PE15.1x | E20.5% | 3.9% | Capital Goods | ||
RTV | €2.56 | 4.1% | -5.9% | €39.2m | €2.80 | PS13.9x | E116.8% | n/a | Media | ||
MTX | €250.30 | -1.3% | 11.7% | €13.5b | €248.95 | PS2.5x | E34.9% | 0.8% | Capital Goods | ||
TTR1 | €17.85 | -5.6% | -33.6% | €123.3m | €21.50 | PE19.3x | E29.4% | 3.5% | Capital Goods | ||
RSL2 | €18.50 | -5.1% | -18.9% | €119.1m | €30.00 | PB1.7x | E58.9% | 0% | Capital Goods | ||
ST5 | €30.80 | 1.0% | -4.2% | €433.8m | €39.50 | PE25.7x | E20.6% | 0% | Capital Goods | ||
SANT | €20.06 | 0.4% | 5.1% | €1.2b | €30.42 | PE16.5x | E21.1% | 2.5% | Software | ||
E4C | €13.05 | -4.7% | -37.6% | €45.8m | €40.50 | PE30.2x | E46.7% | 3.6% | Telecom | ||
AEIN | €17.15 | -4.2% | -30.1% | €196.3m | €32.63 | PE14.7x | E25.2% | 2.9% | Software | ||
SAP | €187.76 | -0.04% | 46.2% | €217.6b | €195.71 | PE84.5x | E34.0% | 1.2% | Software | ||
ADS | €231.40 | 5.8% | 34.0% | €41.3b | €224.08 | PE486.1x | E41.3% | 0.3% | Consumer Durables | ||
GXI | €100.70 | -0.3% | -4.7% | €3.2b | €134.45 | PE27.5x | E22.1% | 1.2% | Pharmaceuticals & Biotech | ||
V3S | €10.85 | 0.9% | 96.6% | €87.4m | €10.25 | PS2.4x | E118.7% | 0% | Tech | ||
R3NK | €26.00 | 2.6% | n/a | €2.6b | €31.94 | PE82.6x | E32.6% | 1.2% | Capital Goods | ||
ISHA | €2.02 | -1.9% | 10.4% | €29.5m | €2.60 | PB2.6x | E80.5% | n/a | Software | ||
SJJ | €10.90 | 0% | 23.9% | €114.5m | €19.75 | PS1.2x | E111.5% | 0% | Software | ||
BSL | €11.00 | 0.9% | -32.1% | €338.1m | €15.70 | PS1.8x | E84.0% | 0% | Tech | ||
EQS | €39.40 | 0% | 90.3% | €394.9m | €37.50 | PS5.5x | E115.5% | 0% | Software | ||
LPK | €8.44 | -6.1% | 1.9% | €206.6m | €12.05 | PE62.4x | E51.7% | n/a | Tech |